Consistent with the results from mouse studies, the treatment with anti‐SIRPα mAb significantly enhanced phagocytic activity of human macrophages against human hepatoma cell line, compared with that with isotype‐matched control Ab, whereas that with nti‐CD47mAb rather reduced (Figure 8). The gene discussed is SIRPA; the disease is hepatocellular carcinoma.